Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Psoriasis severity and quality of life appeared to improve with weight-loss interventions in a systematic review.

Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...